Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this observational study is to learn about changes in health in children that develop over time that may impact overall health and a healthy lifespan. The main questions it aims to answer are:
The two parts of the PUER Research study include (1) Baseline health assessment and (2) blood tests including genetic, molecular, and laboratory profiling. The Baseline assessment will consist of a health history questionnaire interview. Genetic assessment will be conducted using peripheral blood samples. Molecular and laboratory assessments will be conducted using peripheral blood samples and, potentially, urine, stool, and/or saliva samples.
The study will result in cross-sectional and longitudinal real world data collection to inform if any tests used can inform of health changes for individuals and may predict long-term health outcomes. Researchers at study sites will not be blinded to the data being collected during this study.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Whole Genome Sequencing Analysis | Genetic | Laboratory blood analysis |
| Measure | Description | Time Frame |
|---|---|---|
| New deviations: 12 months | The number of new deviations from a study subject's baseline profile 12 months after enrollment that were previously not known at time of enrollment. | 12 months |
| New deviations: 6 months | The number of new deviations, not known at the time of enrollment, at 6 months after enrollment. | 6 months |
| New deviations: 18 months | The number of new deviations, not known at the time of enrollment, at 18 months after enrollment. | 18 months |
| New deviations: 24 months | The number of new deviations, not known at the time of enrollment, at 24 months after enrollment. | 24 months |
| New deviations: 36 months | The number of new deviations, not known at the time of enrollment, at 36 months after enrollment. | 36 months |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Medications | The number and change in the number of medications taken by an individual at 6 months, 12 months, 18 months, 24 months, and 36 months after enrollment. | 6 months, 12 months, 18 months, 24 months, and 36 months after enrollment. |
| Dietary supplements |
Inclusion Criteria:
To participate in the study, patients must meet the following criteria:
Male or non-pregnant female; age 6 to less than 18.
Females of childbearing potential (WOCBP) must have a negative urine pregnancy test (UPT) at all visits.
Presence of
Approval is at the sole discretion of the sponsor.
Exclusion Criteria:
Patients who meet any of the following criteria will be excluded from study participation:
Not provided
Not provided
Not provided
Male or non-pregnant female; age 6 to less than 18.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Szilard Voros, MD | Principal Investigator | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Puer Research, LLC | Atlanta | Georgia | 30350 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 25637381 | Result | Amendola LM, Dorschner MO, Robertson PD, Salama JS, Hart R, Shirts BH, Murray ML, Tokita MJ, Gallego CJ, Kim DS, Bennett JT, Crosslin DR, Ranchalis J, Jones KL, Rosenthal EA, Jarvik ER, Itsara A, Turner EH, Herman DS, Schleit J, Burt A, Jamal SM, Abrudan JL, Johnson AD, Conlin LK, Dulik MC, Santani A, Metterville DR, Kelly M, Foreman AK, Lee K, Taylor KD, Guo X, Crooks K, Kiedrowski LA, Raffel LJ, Gordon O, Machini K, Desnick RJ, Biesecker LG, Lubitz SA, Mulchandani S, Cooper GM, Joffe S, Richards CS, Yang Y, Rotter JI, Rich SS, O'Donnell CJ, Berg JS, Spinner NB, Evans JP, Fullerton SM, Leppig KA, Bennett RL, Bird T, Sybert VP, Grady WM, Tabor HK, Kim JH, Bamshad MJ, Wilfond B, Motulsky AG, Scott CR, Pritchard CC, Walsh TD, Burke W, Raskind WH, Byers P, Hisama FM, Rehm H, Nickerson DA, Jarvik GP. Actionable exomic incidental findings in 6503 participants: challenges of variant classification. Genome Res. 2015 Mar;25(3):305-15. doi: 10.1101/gr.183483.114. Epub 2015 Jan 30. | |
| 23928561 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Whole Genome Sequencing Analysis
The number and change in the number of dietary supplements taken by an individual at 6 months, 12 months, 18 months, 24 months, and 36 months after enrollment. |
| 6 months, 12 months, 18 months, 24 months, and 36 months after enrollment. |
| Result |
| Bromberg Y. Building a genome analysis pipeline to predict disease risk and prevent disease. J Mol Biol. 2013 Nov 1;425(21):3993-4005. doi: 10.1016/j.jmb.2013.07.038. Epub 2013 Aug 5. |
| 24055113 | Result | Dorschner MO, Amendola LM, Turner EH, Robertson PD, Shirts BH, Gallego CJ, Bennett RL, Jones KL, Tokita MJ, Bennett JT, Kim JH, Rosenthal EA, Kim DS; National Heart, Lung, and Blood Institute Grand Opportunity Exome Sequencing Project; Tabor HK, Bamshad MJ, Motulsky AG, Scott CR, Pritchard CC, Walsh T, Burke W, Raskind WH, Byers P, Hisama FM, Nickerson DA, Jarvik GP. Actionable, pathogenic incidental findings in 1,000 participants' exomes. Am J Hum Genet. 2013 Oct 3;93(4):631-40. doi: 10.1016/j.ajhg.2013.08.006. Epub 2013 Sep 19. |
| 18718552 | Result | Han X, Aslanian A, Yates JR 3rd. Mass spectrometry for proteomics. Curr Opin Chem Biol. 2008 Oct;12(5):483-90. doi: 10.1016/j.cbpa.2008.07.024. |
| 25572254 | Result | Scaria V. Personal genomes, participatory genomics and the anonymity-privacy conundrum. J Genet. 2014 Dec;93(3):917-20. doi: 10.1007/s12041-014-0451-3. No abstract available. |
| 25925459 | Result | Schork NJ. Personalized medicine: Time for one-person trials. Nature. 2015 Apr 30;520(7549):609-11. doi: 10.1038/520609a. No abstract available. |